VYNE Therapeutics’ (VYNE) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of VYNE Therapeutics (NASDAQ:VYNE) in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a $5.75 price target on the stock.

Separately, BTIG Research initiated coverage on shares of VYNE Therapeutics in a report on Monday, November 18th. They issued a “buy” rating and a $8.00 target price on the stock.

VYNE Therapeutics Stock Down 8.9 %

NASDAQ VYNE opened at $2.75 on Tuesday. The business’s fifty day simple moving average is $2.98 and its 200-day simple moving average is $2.35. The firm has a market cap of $40.57 million, a PE ratio of -3.20 and a beta of 1.30. VYNE Therapeutics has a 52 week low of $1.57 and a 52 week high of $4.30.

Institutional Investors Weigh In On VYNE Therapeutics

An institutional investor recently bought a new position in VYNE Therapeutics stock. Lynx1 Capital Management LP purchased a new position in shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 16,194 shares of the company’s stock, valued at approximately $32,000. VYNE Therapeutics accounts for 0.0% of Lynx1 Capital Management LP’s investment portfolio, making the stock its 17th biggest holding. Lynx1 Capital Management LP owned about 0.11% of VYNE Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 83.78% of the company’s stock.

About VYNE Therapeutics

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.